medRxiv preprint doi: https://doi.org/10.1101/2021.12.23.21268298; this version posted December 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Persistent symptoms among children and adolescents with and without anti-SARS-CoV-2 antibodies: a population-based serological study in Geneva, Switzerland

Authors: Roxane Dumont¹ M.Sc, Mayssam Nehme M.D², Elsa Lorthe¹ RM Ph.D, Carlos de Mestral¹ Ph.D, Viviane Richard¹ M.Sc, Hélène Baysson^{1,3} Ph.D, Francesco Pennacchio¹ PhD, Julien Lamour¹ M.Sc, Claire Semaani¹ M.A, María-Eugenia Zaballa¹ PhD, Nick Pullen¹ PhD, Anne Perrin M.D⁴, Arnaud G. L'Huillier M.D⁴, Klara M. Posfay-Barbe⁴ M.D. M.Sc, Idris Guessous^{2,3*} M.D, Ph.D, Silvia Stringhini^{1,3,5*} Ph.D, on behalf of the Specchio-COVID19 study group.

- 1 Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland
- 2 Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland
- 3 Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- 4 Division of General Pediatrics, Department of Woman, Child, and Adolescent Medicine, Geneva University Hospitals, Switzerland
- 5 University Center for General Medicine and Public Health, University of Lausanne, Switzerland

*Equal contribution

Specchio-COVID19 study group

Isabelle Arm-Vernez, Andrew S Azman, Fatim Ba, Oumar Ba, Delphine Bachmann, Jean-François Balavoine, Michael Balavoine, Rémy Barbe, Hélène Baysson, Lison Beigbeder, Julie Berthelot, Patrick Bleich, Gaëlle Bryand, François Chappuis, Prune Collombet, Delphine Courvoisier, Alain Cudet, Carlos de Mestral Vargas, Paola D'ippolito, Richard Dubos, Roxane Dumont, Isabella Eckerle, Nacira El Merjani, Antoine Flahault, Natalie Francioli, Marion Frangville, Idris Guessous, Séverine Harnal, Samia Hurst, Laurent Kaiser, Omar Kherad, Julien Lamour, Pierre Lescuyer, François L'Huissier, Fanny-Blanche Lombard, Andrea Jutta Loizeau, Elsa Lorthe, Chantal Martinez, Lucie Ménard, Lakshmi Menon, Ludovic Metral-Boffod, Benjamin Meyer, Alexandre Moulin, Mayssam Nehme, Natacha Noël, Francesco Pennacchio, Javier Perez-Saez, Giovanni Piumatti, Didier Pittet, Jane Portier, Klara M Posfay-Barbe, Géraldine Poulain, Caroline Pugin, Nick Pullen, Zo Francia Randrianandrasana, Aude Richard, Viviane Richard, Frederic Rinaldi, Jessica Rizzo, Khadija Samir, Claire Semaani, Silvia Stringhini, Stéphanie Testini, Deborah Urrutia Rivas, Jennifer Villers, Guillemette Violot, Nicolas Vuilleumier, Ania Wisniak, Sabine Yerly, María-Eugenia Zaballa

Corresponding author

Silvia Stringhini <u>silvia.stringhini@hcuge.ch</u> Unité d'épidémiologie populationnelle Rue Jean-Violette 29 1205 Genève Switzerland +41 22 305 58 61

Acknowledgments

We are grateful to the staff of the Unit of Population Epidemiology of the HUG Division of Primary Care Medicine as well as to all participants whose contributions were invaluable to the study.

Conflict of interest

None of the funding institutions participated in the conduct of the research or in the preparation of the article.

Author Contributions

The idea for the study originally came from CM, RD, IG and SS. RD, CM, MN and HB carried out the literature search. SS, HB, FP, MEZ, CS, JL and VR conceptualized, designed the study and acquired the data. RD, NP and VR performed data analysis. RD, CM, SS and EL wrote the first draft of the manuscript. All authors have read, critically revised and approved the final version of this manuscript.

Ethics and dissemination

The Specchio-COVID19 study was approved by the Cantonal Research Ethics Commission of Geneva, Switzerland (CCER Project ID 2020-00881).

ABSTRACT

Background

It is now established that a significant proportion of adults experience persistent symptoms after SARS-CoV-2 infection. However, evidence for children and adolescents is still inconclusive. In this population-based study, we examine the proportion of children and adolescents reporting persistent symptoms after SARS-CoV-2 infection, as assessed by serological status, and compare this to a seronegative control group.

Methods

We conducted a serosurvey in June-July 2021, recruiting 660 children and adolescents from 391 households selected randomly from the Geneva population. We tested participants for anti-SARS-CoV-2 antibodies targeting the nucleocapsid (N) protein to determine previous infection. A parent filled a questionnaire including questions on COVID-19-related symptoms lasting at least 2 weeks.

Findings

Among children seropositive for anti-SARS-CoV-2 antibodies, the sex- and age-adjusted prevalence of symptoms lasting longer than two weeks was 18.3%, compared to 11.1% among seronegative children (prevalence difference ($\Delta a Prev$)=7.2%, 95%CI:1.5-13.0). Main symptoms declared among seropositive children were fatigue (11.5%) and headache (11.1%). For 8.6% (aPrev, 95%CI: 4.7-12.5) of seropositives, these symptoms were declared to be highly limiting of daily activities. Adolescents aged 12-17 years had a higher adjusted prevalence of persistent symptoms (aPrev=29.1%, 95%CI:19.4-38.7) than younger children. Comparing seropositive and seronegative adolescents, the estimated prevalence of symptoms lasting over four weeks is 4.4% ($\Delta a Prev$, 95%CI:-3.8-13.6).

Interpretation

A significant proportion of children aged 12 to 17 years had symptoms lasting over two weeks after SARS-CoV-2 infection, with an estimated prevalence of symptoms lasting over 4 weeks of 4.4% in this age group. This represents a large number of adolescents in absolute terms, and should raise concern in the context of unknown long-term evolution of symptoms. Younger children appear to experience long-lasting symptoms less frequently, as no difference was observed between the seropositive and seronegative sample. Further studies with larger samples sizes are needed.

Funding

Swiss Federal Office of Public Health, Geneva General Directorate of Health, HUG Private Foundation, SSPH+,

Fondation des Grangettes.

Keywords: Long COVID; post-COVID, Post-acute sequelae of SARS-CoV-2, PASC, children; adolescents,

persistent symptoms; SARS-CoV-2; Switzerland

Word count

Abstract: 293

Main text: 2791

List of abbreviations ΔaPrev: adjusted Prevalence Difference aPrev: adjusted Prevalence aPR: adjusted Prevalence Ratio CI: Confidence interval COVID-19: Coronavirus disease 2019 SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

Introduction

Long COVID or post-COVID syndrome refers to individuals who experience long-lasting symptoms weeks to months following a SARS-CoV-2 infection [1-2]. Evidence to date indicates that more than one third of adults who had mild to severe COVID-19 experience persistent symptoms several months after infection [3–6]. Risk factors include female sex, middle age, comorbidities and the number of symptoms in the acute phase [7]. However, young and previously healthy persons are also frequently affected [8]. As such, long COVID represents an increasing public health concern, potentially preventing affected individuals from returning to the workforce and continuing to burden the healthcare system. If substantial evidence is starting to emerge around long COVID in adults, pediatric long COVID has received much less attention [1]-[9]. To date, there is no generalized definition, nor a recognized diagnostic test for long COVID among children and no precise understanding of the duration of symptoms that justifies the diagnosis.

The pandemic has profoundly impacted directly or indirectly the lives of children and adolescents worldwide in terms of daily life and habits, mental and physical health, social behaviors and schooling [10]. Although they appear to be less susceptible to severe forms of COVID-19 compared to adults [11], recent evidence suggests that an undetermined proportion of infected children may also experience persistent symptoms post infection. Studies from Australia [12], Italy [13], England and Wales [3], and Switzerland [14] have reported prevalence estimates of persistent symptoms lasting more than 4 weeks ranging from 4.6% to 24.0%. The most frequently reported symptoms are fatigue, insomnia, respiratory symptoms (including chest pain and tightness), nasal congestion, muscle and joint pain and difficulty concentrating, which have been reported to last from four weeks up to 4 months [3], [13-15]. These studies differed considerably in their methodological approaches, their assessment of previous infection, sample size, and follow-up periods, so that the actual prevalence of longlasting symptoms among children and adolescents is still debated. Importantly, most studies were based on clinical samples of confirmed cases, while only one study [14] included data from a population-based serosurvey. Population-based serological studies have the advantage of including, by definition, a representative sample of the population which includes severe, mild and asymptomatic infections, giving a more accurate estimation of the number of children infected (denominator). The difference between seropositive and seronegative also allows the distinction of persistent symptoms due to COVID-19 from symptoms due to other viruses. Understanding the frequency, duration and severity of persistent symptoms following SARS-CoV-2 infection in children is essential to guide public health strategies targeting this age group (for example, preventive measures in schools or vaccination programs), as well as to monitor the long-term physical and

mental health impact of the pandemic. Using a representative sample of the general population of the canton of Geneva, Switzerland, we aimed to determine the proportion of children and adolescents reporting persistent symptoms after SARS-CoV-2 infection, as assessed by serological status, compared to seronegative children and adolescents and to identify risk factors of experiencing persistent symptoms.

Methods

Study population

Participants from a random sample of the general population of the state of Geneva, Switzerland, were invited to take part in a serological survey between June 1st and July 7th, 2021 [16]. Lists of residents were provided by the Swiss Federal Office of Statistics within the framework of the Corona Immunitas Research project [17]. As per the study protocol, randomly selected children and adolescents aged between 6 months and 17 years were invited to participate with their family members. Overall, 22.3% of the invited families participated (Figure S1). After providing written informed consent, participants provided a venous blood sample. In each family, one of the parents completed a socio-demographic online questionnaire about themselves, the household and their child(ren). For children from 2 years old, the questionnaire included questions on COVID-19 persistent symptoms.

Measures

Parents were asked if their child(ren) had experienced symptoms lasting at least 2 weeks. Parents could choose from an exhaustive list of 37 symptoms based on the literature at the time, grouped into six general categories of symptoms: fatigue, respiratory, gastrointestinal, musculoskeletal, neurological and dermatological symptoms (Table S1). For each symptom, details on the duration (2 to 3 weeks, 3 to 4 weeks, or more than 4 weeks) and impact on the child's daily activities were collected. The impact/limitation of each selected symptom was based on the following question: "On a scale of 1 to 10, to what extent is this symptom limiting the child's usual activities (attendance at school, nursery, studies, sports, games, etc.)? (1 very weak limitation - 10 strong limitation)". We subsequently created a dichotomous variable where symptoms rated 6 or higher were considered as having a strong limitation on the child's daily life.

Serological tests were based on the semiquantitative commercially-available immunoassay Roche Elecsys anti-SARS-CoV-2 N and seropositivity was defined using the manufacturer's provided cut-off index of ≥ 1.0 [18] (See supplementary material). The Roche N serological test identifies anti-N antibodies, which are not produced

following vaccination with mRNA vaccines used in Geneva to date, such as the Pfizer-BioNTech BNT162b2 and Moderna mRNA 1273 vaccines, and are therefore only detected if the individual was infected with SARS-CoV-2. Using this test allowed us to remove the effect of vaccination.

Parental education was categorized as primary for compulsory schooling, secondary for apprenticeship and high school, and tertiary for university. Household financial status was defined as average to poor if participants chose one of the following statements about their financial situation: "I have to be careful with my expenses and an unexpected event could put me into financial difficulty" or "I cannot cover my needs with my income and I need external support".

Statistical analysis

We compared the distribution of sociodemographic and COVID-19-related characteristics between children who tested positive for anti-SARS-CoV-2 antibodies and children who tested negative, overall and stratified into three age groups (2 to 5, 6 to 11 and 12 to 17). Participants with missing data were excluded. To estimate prevalence (95% confidence intervals) and prevalence differences, we used marginal prediction after logistic regression, adjusting for age and sex. To calculate prevalence ratios (95% CI), we used Poisson regression with robust variance, based on the sandwich estimator [19]. To account for the fact that many children were siblings, we conducted additional analyses on the prevalence ratio estimation using mixed-effect Poisson regression with robust variance [20]. Statistical significance was defined at a level of confidence of 95% and all analyses were performed with R (version 4.0.3).

Results

Our sample comprised 660 children aged 2 to 17 years (49.4% girls, mean age 9.3 years [SD=4.5]) from 391 households (Table 1). A majority of parents (58.6%) had a tertiary education level, 7.6% had a primary education level, and 22.1% reported having an average to poor financial situation.

Overall, 13.5% of children (adjusted prevalence=13.3%, 95%CI: 10.4-16.2) were reported by their parent as having experienced at least one symptom that lasted more than two weeks since the beginning of the pandemic. Specifically, 18.3% (95%CI: 13.0-23.6) of seropositive children had symptoms lasting more than two weeks vs 11.1% (95%CI: 8.2-14.0), among seronegative children, with an adjusted prevalence difference of 7.2% (95%CI: 1.5-13.0) (Table 1). Among seropositive participants, 14.8% (95%CI: 9.9-19.7) reported symptoms lasting 2-3 weeks, 1.0% (95%CI: 0.0-2.3) 3-4 weeks and 2.4% (95%CI: 0.3-4.5) more than four weeks. Among

seronegative participants, the corresponding adjusted prevalence were 5.2% (95%CI 3.2-7.3), 0.9% (95%CI: 0.0-1.8), and 3.3% (95%CI: 1.7-5.0). Moreover, for 8.6% (95%CI: 4.7-12.5) of seropositive children, these persistent symptoms were reported as highly limiting and resulting in a daily burden, compared to 2.9% (95%CI: 1.3-4.5) among seronegatives.

The most frequently reported symptoms by seropositive participants were fatigue (11.6%), headache (11.1%), fever (6.2%), runny nose (6.2%), loss of smell (4.8%) and loss of taste (3.8%). Among seronegatives, the most frequently reported symptoms were fatigue (6.2%), runny nose (5.9%), cough (4.2%) and sore throat (3.1%) (Table S1).

The age- and sex-adjusted prevalence of persistent symptoms varied across age groups (Figure 1, Table S2) and differed by serological status. Among seropositive adolescents aged 12 to 17 years, 29.0% (95%CI: 19.4-38.7) reported persistent symptoms, while the age-and-sex adjusted prevalence was 8.9% (95%CI: 4.4-13.4) among seronegative participants of the same age (Prevalence difference ($\Delta a Prev$)=20.1%, 95%CI: 10.6-29.7). Differences between seropositive and seronegative participants were not significant among children aged 6 to 11 years ($\Delta a Prev$ =-0.5%, 95%CI: -8.2-7.1) and those aged 2 to 5 years ($\Delta a Prev$ =-0.8%, 95%CI: -13.4-11.6).

Among seropositive adolescents aged 12 to 17 years, 5.5% (95%CI: 0.5-10.3) reported experiencing symptoms lasting longer than four weeks, while the prevalence among seronegative was 1.1% (95%CI: 0.0-2.6) with an adjusted prevalence difference in this age group of 4.4% (95%CI:-3.8-13.6). The most frequently reported symptoms category in this age group were fatigue ($\Delta a Prev = 13.4\%$, 95%CI: 4.7-22.1), neurological (mostly headaches) ($\Delta a Prev = 15.8\%$, 95%CI: 5.6-26.7) and respiratory symptoms ($\Delta a Prev = 11.8\%$, 95%CI: 2.7-21.6), (Figure S2).

Overall, seropositive children and adolescents were 62% more likely than seronegatives to experience symptoms lasting more than 2 weeks (aPR = 1.62, 95%CI: 1.10-2.39). In sub-analyses focusing only on seropositive children, we observed that seropositive children whose parents had a primary education level were almost three times more likely (aPR = 2.97, 95%CI: 1.11-7.96) and those whose parents have a secondary education level twice as likely (aPR = 2.10, 95%CI: 1.07-4.12) to experience symptoms lasting more than two weeks, compared with seropositive children whose parents had a tertiary education level. Similarly, parents from households with an average to poor financial status were twice as likely to declare long-lasting symptoms for their children than parents with high financial status (aPR=2.18, 95%CI 1.09-4.35) (Table 3).

Discussion

In this population-based study, 13.3% of children experienced symptoms lasting more than 2 weeks since the beginning of the COVID-19 pandemic. Stratifying by age groups, the proportion of children experiencing persistent symptoms was significantly different (20.1 percentage points higher) between seropositive and seronegative adolescents (12 to 17 years old). For symptoms lasting more than 4 weeks among this age group, the adjusted prevalence difference between seronegatives and seropositives was 4.4%. No difference in reported persistent symptoms was observed between the seropositive and seronegative children younger than 12 years old.

In our study, we investigated symptoms that lasted at least 2 weeks, and we assessed a large variety of potential post-SARS-CoV-2 infection symptoms. Among children, there is currently no generalized definition, nor a diagnostic test of long COVID, and no precise understanding of the duration of symptoms that justifies the diagnosis. According to the World Health Organization, long COVID is considered when persistent symptoms last at least 12 weeks in adults but this definition may be different for children [2]. Among children, symptoms lasting up to 4 weeks are considered as potentially acute or subacute symptoms, and most studies on long COVID among children have used a duration ranging from 4 to 8 weeks to justify the diagnosis. In our study, the majority of children declared symptoms lasting 2 to 4 weeks, suggesting that symptoms were mostly acute or subacute and not long-lasting.

Cross-sectional studies on long COVID among children[3], [12-14] have reported prevalence estimates of persistent symptoms lasting more than 4 weeks ranging from 4.6% to 24.0%, with a strong heterogeneity in study design, inclusion criteria and outcomes. In our sample, 3.0% of seropositive children were declared as having symptoms lasting longer than 4 weeks; this proportion was 5.5% among seropositive adolescents aged 12 to 17, and 1.1% among seronegative participants in the same age group. This suggests that the prevalence of long COVID, defined as persistent symptoms lasting more than 4 weeks, may be around 4.4% in adolescents aged 12 to 17. Long-COVID as per this definition seems to affect fewer children below the age of 12 years in our sample. However, it needs to be noted that our sample does not allow for enough statistical power to capture small proportions; for this a much larger sample would be needed.

Importantly, our analysis is based on a population-based sample where serological status was used to identify previous infection. Compared to clinical studies or studies of PCR-confirmed cases, this design has the advantage of including severe, mild and asymptomatic infections, thereby yielding a more accurate denominator

of the proportion of children infected. The latter may also explain why our estimated prevalence of long COVID is low compared to other studies. It also gives a seronegative control group, which allows us to distinguish symptoms that may be due to long COVID from symptoms due to other viruses or to the pandemic context (school closures, fewer social interactions, being unable to do sports and other activities or seeing family and friends suffering from COVID-19)[21].

Our results highlight the importance of stratifying by age groups when examining long COVID in children, as the prevalence and characteristics of long COVID likely vary between younger children and adolescents. Recent studies show that one third of adults present symptoms 30 to 45 days after their infection and those symptoms can persist for many months [22]. Our estimation of 4.4% prevalence of symptoms lasting over 4 weeks in the 12 to 17 age group suggests that adolescents remain less likely than adults to experience long-term symptoms, although this number still represents a large number of adolescents in absolute terms. The overall duration of long COVID in children and adolescents still needs to be studied and defined.

The lives of children and adolescents have been strongly disrupted since the beginning of the pandemic and concerns have been raised about the long term mental and physical health impact of the crisis [23]. In addition, evidence of persistent symptoms among children and a relatively large proportion declaring having had severe symptoms that resulted in a daily burden (even if not all long term), highlight the importance of monitoring the physical and mental impact of COVID-19 on this generation of children and adolescents.

In analyses restricted to seropositive children, we highlighted that children from households with a disadvantaged socioeconomic background were more likely to report symptoms lasting at least 2 weeks. To our knowledge, no previous study has assessed socioeconomic inequalities in long COVID in children nor in adults. These findings are not surprising as they reflect an extensive body of literature linking socioeconomic conditions to several negative health outcomes in children and adolescents [24].

The major strength of this study is that it relies on a randomly selected population-based sample. To date, very few studies on long COVID among children are population-based, and include children from the age of 2. Previous SARS-CoV-2 infection was assessed with an objective measure, enabling us to benefit from a seronegative control group. Relying on serological tests rather than only on confirmed infections gives the advantage of including mild and asymptomatic COVID-19 cases and to get a more precise denominator for SARS-CoV-2 infections. Also, it prevents the bias of participants over-reporting persistent symptoms when

knowing they have been infected [25]. To our knowledge, only one previous study on long COVID in children was based on a serosurvey [14].

The study also has several limitations. First, it relies on parent-reported data on questionnaires without clinical assessment and objective measures. The presence and duration of persistent symptoms among children is based on the parental point of view, which can be subjective due to a potential memory bias and influenced by the parent's background as well as the general household environment [21]. Also, the lack of information on the duration of persistent symptoms after four weeks as well as symptoms' daily burden not being based on a standardized measure complicates the classification and diagnosis of long COVID. Finally, our sample is relatively small, with less than 10% of power to detect a difference of 1% in the prevalence of symptoms lasting more than 4 weeks between the seropositive and the seronegative sample.

Conclusion

Our findings revealed that a significant proportion of children aged 12 to 17 years have symptoms lasting over two weeks after SARS-COV-2 infection, as assessed by serological status before vaccination. The estimated prevalence of symptoms lasting over 4 weeks is of 4.4% in this age group which suggests that adolescents are less likely than adults to experience long-term symptoms. This proportion represents a large number of adolescents in absolute terms, and should raise concern in the context of unknown long term evolution of symptoms. Children aged 2 to 11 years appear to experience fewer long-lasting symptoms related to SARS-CoV-2 infection, as no difference was observed between the seropositive and seronegative sample. However, our power to detect small differences was limited by the sample size, and further larger studies are needed to assess the prevalence of persistent symptoms among younger children. Monitoring the evolution of long COVID among children and adolescents is highly important as the long term physical and mental impact of COVID-19 persistent symptoms remains unclear and adequate public health policies are needed in terms of schooling and vaccination.

REFERENCE

[1] T. Lancet, 'Facing up to long COVID', Lancet (London, England), vol. 396, no. 10266, p. 1861, 2020.

[2] J. V. Diaz and J. B. Soriano, 'A Delphi consensus to advance on a Clinical Case Definition for Post COVID-19 condition: A WHO protocol', 2021.

[3] F. Miller *et al.*, 'Prevalence of persistent symptoms in children during the COVID-19 pandemic: evidence from a household cohort study in England and Wales', *medRxiv*, 2021.

[4] E. Mahase, 'Covid-19: What do we know about "long covid"?', *bmj*, vol. 370, 2020.

[5] J. K. Logue *et al.*, 'Sequelae in adults at 6 months after COVID-19 infection', *JAMA network open*, vol. 4, no. 2, pp. e210830–e210830, 2021.

[6] A. Carfi, R. Bernabei, and F. Landi, 'Persistent symptoms in patients after acute COVID-19', *Jama*, vol. 324, no. 6, pp. 603–605, 2020.

[7] D. Ayoubkhani, 'Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021', *Off Natl Stat*, pp. 1–16, 2021.

[8] E. Cirulli *et al.*, 'Long-term COVID-19 symptoms in a large unselected population', *medrxiv*, 2020.

[9] T. H. de Souza, J. A. Nadal, R. J. Nogueira, R. M. Pereira, and M. B. Brandão, 'Clinical manifestations of children with COVID-19: a systematic review', *Pediatric pulmonology*, vol. 55, no. 8, pp. 1892–1899, 2020.

[10] U. Ravens-Sieberer *et al.*, 'Mental health and quality of life in children and adolescents during the COVID-19 pandemic—results of the COPSY study', *Deutsches Ärzteblatt International*, vol. 117, no. 48, p. 828, 2020.

[11] R. M. Viner *et al.*, 'Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis', *JAMA pediatrics*, vol. 175, no. 2, pp. 143–156, 2021.

[12] D. Say, N. Crawford, S. McNab, D. Wurzel, A. Steer, and S. Tosif, 'Post-acute COVID-19 outcomes in children with mild and asymptomatic disease', *The Lancet Child & Adolescent Health*, vol. 5, no. 6, pp. e22–e23, 2021.

[13] D. Buonsenso *et al.*, 'Preliminary evidence on long COVID in children', *MedRxiv*, 2021.

[14] T. Radtke, A. Ulyte, M. A. Puhan, and S. Kriemler, 'Long-term symptoms after SARS-CoV-2 infection in children and adolescents', *Jama*, vol. 326, no. 9, pp. 869–871, 2021.

[15] P. Venkatesan, 'NICE guideline on long COVID', *The Lancet Respiratory Medicine*, vol. 9, no. 2, p. 129, 2021.

[16] S. Stringhini *et al.*, 'Seroprevalence of anti-SARS-CoV-2 antibodies six months into the vaccination campaign in Geneva, Switzerland', *medRxiv*, 2021.

[17] E. A. West *et al.*, 'Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland', *International journal of public health*, vol. 65, no. 9, pp. 1529–1548, 2020.

[18] J. Perez-Saez *et al.*, 'Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance', *Clinical Microbiology and Infection*, 2021.

[19] A. J. Barros and V. N. Hirakata, 'Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio', BMC medical research methodology, vol. 3, no. 1, pp. 1–13, 2003.

[20] F. L. Huang, 'Alternatives to Logistic Regression Models when Analyzing Cluster Randomized Trials with Binary Outcomes', Prevention Science, pp. 1-10, 2021.

[21] J. Blankenburg et al., 'Mental Health of Adolescents in the Pandemic: Long-COVID-19 or Long-Pandemic Syndrome?', Available at SSRN 3844826, 2021.

[22] M. Nehme, O. Braillard, F. Chappuis, D. S. Courvoisier, and I. Guessous, 'Prevalence of symptoms more than seven months after diagnosis of symptomatic COVID-19 in an outpatient setting', Annals of internal medicine, 2021.

C. S. de Figueiredo et al., 'COVID-19 pandemic impact on children and adolescents' mental health: [23] biological, environmental, and social factors', Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 106, p. 110171, 2021.

[24] N. H. Rod, J. Bengtsson, L. K. Elsenburg, D. Taylor-Robinson, and A. Rieckmann, 'Hospitalisation patterns among children exposed to childhood adversity: a population-based cohort study of half a million children', The Lancet Public Health, 2021.

[25] J. Matta et al., 'Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology pcr Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic', JAMA internal medicine, 2021.

[

Table 1. Descriptive statistics of the study population, stratified by serological status

	All participants N=660	Seronegative N=453	Seropositive ^b N=207	Adjusted difference
Sex N (%)	2			
Female	326 (49.4)	229 (50.6)	97 (46.9)	
Age (mean, SD)	9.3 (4.5)	8.9 (4.7)	10.2 (3.9)	-
Age group in years N (%)		,	()	-
2-5	147 (22.3)	118 (26.1)	29 (14.0)	-
6-11	271 (41.1)	180 (39.7)	91 (44.0)	_
12-17	242 (36.6)	155 (34.2)	87 (42.0)	_
Parental education ^a N (%)	242 (30.0)	155 (54.2)	07 (42.0)	
Tertiary	386 (58.6)	274 (60.6)	112 (54.1)	_
Secondary	223 (33.8)	145 (32.1)	78 (37.7)	-
Primary	50 (7.6)	33 (7.3)	17 (8.2)	-
	50 (7.6)	33 (7.3)	17 (8.2)	-
Financial situation ^a N (%)	440 (60.1)	216 (60.0)	100 (64.0)	
High	449 (68.1)	316 (69.8)	133 (64.3)	-
Average to poor	146 (22.1)	92 (20.3)	54 (26.1)	-
Declined to answer	65 (9.8)	45 (9.9)	20 (9.6)	-
Symptoms > 2 weeks				
N (%)	89 (13.5)	50 (11.0)	39 (18.8)	
aPrevalence (95%CI) ^c	13.3 (10.4-16.2)	11.1 (8.2-14.0)	18.3 (13.0-23.6)	7.2 (1.5-13.0)*
Reported symptoms				
Fatigue				
N (%)	52 (7.9)	28 (6.2)	24 (11.6)	
aPrevalence (95% CI) ^c	7.3 (5.1-9.5)	5.9 (3.7-8.1)	10.3 (6.1-14.4)	4.4 (0.2-9.0)*
Respiratory				
N (%)	59 (8.9)	35 (7.7)	24 (11.6)	
aPrevalence (95% CI) ^c	8.9 (6.4-11.3)	7.6 (5.1-10)	11.7 (7.3-16.1)	4.1 (0.0-9.2)
Gastrointestinal				
N (%)	41 (6.2)	22 (4.9)	19 (9.2)	
aPrevalence (95% CI) ^c	5.7 (3.8-7.6)	4.5 (2.6-6.4)	8.4 (4.6-12.2)	3.9 (0.3-8.1)
Musculoskeletal	5.7 (5.6 7.6)	1.5 (2.0 0.1)	0.1 (1.0 12.2)	5.5 (0.5 0.1)
N (%)	19 (2.9)	7 (1.5)	12 (5.8)	
aPrevalence (95% CI) ^c	2.1 (1.2-3.1)	1.1 (0.2-2.1)	4.2 (1.4-7.1)	4.2 (1.4-7.0)*
Neurological	2.1 (1.2-3.1)	1.1 (0.2-2.1)	4.2 (1.4-7.1)	4.2 (1.4-7.0)
N (%)	(7, (7, 1))	20(4,4)	27(12.0)	
	47 (7.1)	20 (4.4)	27 (13.0)	7.0 (2.1.10.0)**
aPrevalence (95% CI) ^c	6.1 (4.3-7.9)	3.8 (2.0-5.6)	11.0 (6.7-15.4)	7.2 (3.1-12.8)**
Dermatological		10 (0.0)	1 (1 0)	
N (%)	16 (2.4)	12 (2.6)	4 (1.9)	
aPrevalence (95% CI) ^c	2.3 (0.9-3.8)	2.5 (1.0-4.0)	1.9 (0.0-3.8)	-0.6 (-4.0-2.7)
Symptoms duration				
2 to 3 weeks				
N (%)	56 (8.5)	24 (5.3)	32 (15.5)	
aPrevalence (95% CI) ^c	8.2 (6.2-10.3)	5.2 (3.2-7.3)	14.8 (9.9-19.7)	9.6 (4.2-15.1)**
3 to 4 weeks				
N (%)	8 (1.2)	5 (1.1)	3 (1.4)	
aPrevalence (95% CI) ^c	1.0 (0.1-1.9)	0.9 (0.0-1.8)	1.0 (0.0-2.3)	0.1 (-2.9-3.1)
More than 4 weeks		(,		
N (%)	20 (3.0)	15 (3.3)	5 (2.4)	
aPrevalence (95% CI) ^c	3.0 (1.4-4.7)	3.3 (1.7-5.0)	2.4 (0.3-4.5)	-0.9 (-3.7-1.8)
Symptoms impact on daily life	5.0 (1.7 7.7)	5.5 (1.7 5.0)	2.1 (0.5 4.5)	0.7 (0.7 1.0)
Low				
	71 (10.9)	41 (0.1)	20 (14 5)	
N (%)	71 (10.8)	41 (9.1)	30 (14.5)	51(00112)*
aPrevalence (95% CI) ^c	10.7 (8.0-13.3)	9.1 (6.4-11.7)	14.2 (9.5-19.0)	5.1 (-0.9-11.3)*
High			20 /0 -	
N (%)	34 (5.2)	14 (3.1)	20 (9.7)	
aPrevalence (95% CI) ^c Some of the children participating in the stud	4.7 (3.2-6.3)	2.9 (1.3-4.5)	8.6 (4.7-12.5)	5.7 (2.2-9.9)*

^a Some of the children participating in the study are siblings therefore the reported parental and financial situation are presented individually ^b Seropositive is define as naturally infected (Roche-N immunoassays cut-off index ≥ 1.0)

^cAge- and sex-adjusted prevalence and prevalence differences, using marginal prediction of logistic regression and 95% CI were computed using normal approximation and truncated to 0 for the aPrevalence

* indicates p-value <0.05 **indicates p-value <0.01

Table 2. Association between persistent symptoms and serological status

Report of symptoms lasting at least 2 weeks		No (%)	Yes (%)	Prevalence ratio ^a	Prevalence ratio ^b
		N=571	N=89	95% CI	95% CI
Sex	Female	285 (87.2)	42 (12.8)	1.0 (ref)	1.0 (ref)
	Male	280 (85.6)	47 (14.4)	1.11 (0.76-1.64)	1.14 (0.74-1.76
	Diverse	8 (100.0)	0 (0.0)	undefined	undefined
Age (years)	2-5	132 (89.8)	15 (10.2)	1.0 (ref)	1.0 (ref
	6-11	236 (87.1)	35 (12.9)	1.26 (0.71-2.23)	1.54 (0.30-7.83
	12-17	203 (83.9)	39 (16.1)	1.57 (0.90-2.76)	1.61 (0.86-2.98
Serological status	Negative	404 (89.0)	50 (11.0)	1.0 (ref)	1.0 (ref
	Positive	169 (81.2)	39 (18.8)	1.65 (1.13-2.41)*c	1.62 (1.10-2.39)*

variable. ^b Prevalence ratio and 95% confidence interval are from Poisson regression with robust variance and random effect on the household using the GLMMadaptive

package in R, and are adjusted for age, sex, or both according to independent variable. cAdjusting for age and sex

* indicates p-value <0.05

**indicates p-value <0.01

Table 3. Association between persistent symptoms and socioeconomic indicators among seropositive children

Report of symptoms lasting at least 2 weeks, among seropositive		No (%) N=168	Yes (%) N=39	Prevalence ratio ^a (95% CI)	Prevalence ratio ^b (95% CI)
Sex	Female	80 (82.5)	17 (17.5)	1.0 (ref)	1.0 (ref)
	Male	85 (79.4)	22 (20.6)	1.17 (0.66-2.07)	1.18 (0.62-2.23)
	Diverse	3 (100.0)	0 (0.0)	undefined	undefined
Age (years)	2-5	26 (89.7)	3 (10.3)	1.0 (ref)	1.0 (ref)
	6-11	80 (87.9)	11 (12.1)	1.18 (0.35-3.94)	1.27 (0.36-3.96)
	12-17	62 (71.3)	25 (28.7)	2.84 (0.92-8.72)	2.84 (0.85-9.43)
Parental education	Tertiary	99 (88.4)	13 (11.6)	1.0 (ref)	1.0 (ref)
	Secondary	58 (74.4)	20 (25.6)	2.10 (1.11-3.98)*c	2.10 (1.07-4.12)*c
	Primary	11 (64.7)	6 (35.3)	2.98 (1.31-6.79)*c	2.97 (1.11-7.96)*c
Financial situation	High	114 (85.7)	19 (14.3)	1.0 (ref)	1.0 (ref)
	Average to poor	39 (72.2)	15 (27.8)	2.19 (1.22-3.09)*c	2.18 (1.09-4.35)*c
	Declined to answer	15 (75.0)	5 (25.0)	1.54 (0.67-3.53) ^c	1.55 (0.68-3.52) ^c

^aPrevalence ratio and 95% confidence interval are from Poisson regression with robust variance, and are adjusted for age, sex, or both according to independent variable.

^bPrevalence ratio and 95% confidence interval are from Poisson regression with random effect on the household using the GLMMadaptive package in R and are adjusted for age, sex, or both according to independent variable.

^cAdjusting for age and sex * indicates p-value <0.05

**indicates p-value <0.01



